California-based Next Pharmaceuticals has been issued a patent for use of magnolia extracts, a key component in the company's anti-stress ingredient Relora.
The patent, US 6,582,735, relates to the use of Relora to prevent and treat sleeplessness, restlessness and weight gain associated with stress and the stress-related condition 'metabolic syndrome'.
The patent will boost the profile of the small company, adding value to the ingredient for use in supplements and functional foods.
Next Pharmaceuticals president and CEO Bob Garrison said: "Our three human studies along with the findings from our current clinical trial with Relora will provide branding opportunities in some hot markets, including weight control."
Next Pharmaceuticals also makes Nexrutine, said to have anti-inflammatory actions and promote healthy joint and muscle function.